Robert James Wills - 11 Jul 2025 Form 4 Insider Report for Milestone Pharmaceuticals Inc. (MIST)

Reporting relationship: Director
Issuer ticker: MIST
Reported as of: 11 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jul 2025, 16:15:23 UTC
Prior SEC filing: 12 Jun 2025
Next SEC filing: 21 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Jason Minio, Attorney-in-Fact

Key filing fact

Robert James Wills filed Form 4 for Milestone Pharmaceuticals Inc. (MIST) on 15 Jul 2025.

Key facts

This page summarizes Robert James Wills's Form 4 filing for Milestone Pharmaceuticals Inc. (MIST).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 15 Jul 2025, 16:15.

Change

Previous filing in this sequence was filed on 12 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001634189 Primary reporting owner

Wills Robert James

Relationship: Director
Address: C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, QUEBEC, CANADA
Signature: /s/ Jason Minio, Attorney-in-Fact
Signature date: 15 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MIST transaction

Common Shares

Award

Transaction value
Shares: +50,000
Change %: +333%
Price
Shares after: 65,000
Date: 11 Jul 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIST transaction Derivative

Series A Common Warrants (right to buy)

Award

Transaction value
Shares: +50,000
Change %
Price
Shares after: 50,000
Date: 11 Jul 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 50,000
Exercise price: $1.50
Footnotes: F1, F2

MIST transaction Derivative

Series B Common Warrants (right to buy)

Award

Transaction value
Shares: +50,000
Change %
Price
Shares after: 50,000
Date: 11 Jul 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 50,000
Exercise price: $1.88
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The reported securities are included within 50,000 Issuer Units purchased by the Reporting Person for $1.50 per Unit. Each Unit consists of one common share, one Series A common warrant and one Series B common warrant, each warrant represents the right to purchase 50,000 shares of common stock.

Footnote F2

Fully vested and exercisable.